Letters and Corrections1 August 1982Ketoconazole EffectsDAVID A. STEVENS, M.D., PAUL L. WILLIAMS, M.D., ALAN M. SUGAR, M.D., ALLAN PONT, M.D.DAVID A. STEVENS, M.D.Search for more papers by this author, PAUL L. WILLIAMS, M.D.Search for more papers by this author, ALAN M. SUGAR, M.D.Search for more papers by this author, ALLAN PONT, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-97-2-284_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Catanzaro and associates (1) in their article on ketoconazole and coccidioidomycosis cite three earlier studies and comment: ". . . only 20 clinical cases of coccidioidomycosis being treated with ketoconazole have been reported." The three studies cited, however, reported a total of 61 patients with coccidioidomycosis treated with ketoconazole. The number of patients studied was amplified in a subsequent report (2) and other preliminary reports were published in abstract form.Catanzaro and associates suggest the serum half-life of ketoconazole is 5.4 hours, whereas recent pharmacokinetic studies (3) indicate a shorter time of 2.0 to 3.3 hours. Examination...References1. CATANZARO A, EINSTEIN H, and LEVINE B. Ketoconazole for treatment of disseminated coccidioidomycosis. Ann Intern Med. 1982;96:436-40. LinkGoogle Scholar2. STILLER R, DEFELICE R, BRASS C, GALGIANI J, and STEVENS D. Therapy of cutaneous coccidioidomycosis with imidazoles: comparison of results with miconazole and ketoconazole. Pan Amer Health Org Sci Publ. 1980;396:375-81. Google Scholar3. BRASS C, GALGIANI J, BLASCHKE T, DEFELICE R, O'REILLY R, and STEVENS D. Disposition of ketoconazole, an oral antifungal, in man. Antimicrob Agents Chemother. 1982;21:151-8. CrossrefMedlineGoogle Scholar4. PONT A, WILLIAMS P, and LOOSE D. Ketoconazole inhibits adrenal steroid synthesis [Abstract]. Clin Res. 1982;30:99A. Google Scholar5. PONT A, WILLIAMS P, and AZHAR A. Ketoconazole blocks testosterone synthesis [Abstract]. Clin Res. 1982;30:32A. Google Scholar6. ROSS J, LEVINE B, CATANZARO A, EINSTEIN H, SCHILLACI R, and FRIEDMAN P. Ketoconazole for treatment of chronic pulmonary coccidioidomycosis. Ann Intern Med. 1982;96:440-3. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: DAVID A. STEVENS, M.D.; PAUL L. WILLIAMS, M.D.; ALAN M. SUGAR, M.D.; ALLAN PONT, M.D.Affiliations: Santa Clara Valley Medical Center and Institute for Medical Research San Jose Stanford University Medical School Stanford Children's Hospital of San Francisco San Francisco, CA 95128 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byTreatment of Phaeohyphomycosis and Pityriasis VersicolorRole of Animal and Human Pharmacology in Antifungal Drug DesignAdrenal response to corticotropin during therapy with itraconazoleAktuelle lnformationen zur UrologieKetoconazole; Mechanism of Action, Spectrum of Activity, Pharmacokinetics, Drug Interactions, Adverse Reactions and Therapeutic UseKetoconazole: An Orally Effective Antifungal Agent Mechanism of Action, Pharmacology, Clinical Efficacy and Adverse EffectsKetoconazole Therapy in Advanced Prostatic CancerKetoconazoleKetoconazole: A Novel and Rapid Treatment for Advanced Prostatic CancerKetoconazole (Nizoral, Janssen Pharmaceutica, Inc.) 1 August 1982Volume 97, Issue 2Page: 284-285KeywordsCoccidioidomycosisHalf lifePharmacokinetics ePublished: 1 December 2008 Issue Published: 1 August 1982 PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
David A. Stevens (1982) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: